Roderick de Greef net worth and biography

Roderick de Greef Biography and Net Worth

CFO of BioLife Solutions

Roderick (Rod) de Greef has served as BioLife’s Chief Financial Officer since May of 2016. He was additionally appointed Chief Operating Officer in December 2019. Rod has a longstanding association with BioLife, having served as a director of the company from June 2000 through November 2013 and provided the company with strategic and financial consulting services from July 2007 through August 2011.

Due to his extensive experience in business and corporate finance, Rod is in high demand as an officer and director of public companies. He has served as a director and chairman of the Audit Committee of the Board of Directors of Indonesia Energy Corporation Limited since February 2019. Rod has twice served the mobile communications company Pareteum Corporation (2008-2011 and 2015-2017), as a director, Chair of the Audit Committee, and a member of the Nominating and Corporate Governance Committee and the Compensation Committee. Rod was Chairman of the Board at Cambridge Heart, Inc. from November 2008 to October 2013 and went on to serve as President and sole Director of that company’s privately held successor, Cambridge Cardiac Technologies, from November 2013 to October 2014. He served as a director, member of the audit committee and chairman of the compensation committee for Endologix, Inc. from November 2003 to May 2013. From 2001 to 2006, Rod was Executive Vice President and Chief Financial Officer of NASDAQ-listed Cardiac Science, Inc.

Rod has an MBA from the University of Oregon, and a B.A in Economics and International Relations from San Francisco State University.

What is Roderick de Greef's net worth?: The estimated net worth of Roderick de Greef is at least $10.81 million as of March 12th, 2024. Mr. de Greef owns 461,854 shares of BioLife Solutions stock worth more than $10,807,384 as of October 31st. This net worth estimate does not reflect any other investments that Mr. de Greef may own. Additionally, Mr. de Greef receives a salary of $1,630,000.00 as CFO at BioLife Solutions. Learn More about Roderick de Greef's net worth.
How old is Roderick de Greef?: Mr. de Greef is currently 64 years old. There are 5 older executives and no younger executives at BioLife Solutions. Learn More on Roderick de Greef's age.
What is Roderick de Greef's salary?: As the CFO of BioLife Solutions, Inc., Mr. de Greef earns $1,630,000.00 per year. Learn More on Roderick de Greef's salary.
How do I contact Roderick de Greef?: The corporate mailing address for Mr. de Greef and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Roderick de Greef's contact information.
Has Roderick de Greef been buying or selling shares of BioLife Solutions?: Roderick de Greef has not been actively trading shares of BioLife Solutions over the course of the past ninety days. Most recently, Greef Roderick De sold 7,249 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.60, for a transaction totalling $120,333.40. Following the completion of the sale, the chief executive officer now directly owns 461,854 shares of the company's stock, valued at $7,666,776.40. Learn More on Roderick de Greef's trading history.
Who are BioLife Solutions' active insiders?: BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?: In the last twelve months, insiders at the medical equipment provider sold shares 70 times. They sold a total of 92,283 shares worth more than $1,770,306.28. The most recent insider tranaction occured on October, 15th when EVP Aby J Mathew sold 10,000 shares worth more than $232,800.00. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.
Information on this page was last updated on 10/15/2024.

Roderick de Greef Insider Trading History at BioLife Solutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2024	Sell	7,249	$16.60	$120,333.40	461,854
1/19/2024	Sell	2,642	$16.76	$44,279.92	439,897
11/30/2022	Sell	33,905	$20.59	$698,103.95	34,314
11/28/2022	Sell	10,000	$21.12	$211,200.00	69,719
11/23/2022	Sell	4,500	$21.71	$97,695.00	79,719
11/21/2022	Sell	9,500	$21.63	$205,485.00	84,219
11/18/2022	Sell	1,500	$22.13	$33,195.00	93,719
11/16/2022	Sell	1,500	$23.21	$34,815.00	95,219
11/14/2022	Sell	20,000	$23.86	$477,200.00	96,719
10/7/2022	Sell	8,552	$22.69	$194,044.88	116,719
10/3/2022	Sell	1,233	$21.95	$27,064.35	125,271
7/12/2022	Sell	9,158	$15.79	$144,604.82	124,458
4/18/2022	Sell	18,530	$17.59	$325,942.70	129,780
4/7/2022	Sell	10,713	$21.82	$233,757.66	104,464
1/7/2022	Sell	10,816	$30.75	$332,592.00
12/29/2021	Sell	705	$39.37	$27,755.85
11/18/2021	Sell	7,000	$50.75	$355,250.00
11/16/2021	Sell	7,000	$51.39	$359,730.00
10/25/2021	Sell	2,371	$44.62	$105,794.02
10/14/2021	Sell	1,221	$39.97	$48,803.37
9/28/2021	Sell	689	$43.12	$29,709.68
8/19/2021	Sell	12,000	$45.12	$541,440.00	162,853
8/17/2021	Sell	12,000	$44.81	$537,720.00
6/29/2021	Sell	685	$43.75	$29,968.75	174,853
4/15/2021	Sell	5,000	$33.69	$168,450.00	189,538
4/13/2021	Sell	10,919	$35.08	$383,038.52	189,538
4/1/2021	Sell	3,855	$36.53	$140,823.15	186,171
3/26/2021	Sell	2,893	$35.01	$101,283.93	176,239
2/19/2021	Sell	4,509	$40.76	$183,786.84	161,033
2/17/2021	Sell	4,424	$41.55	$183,817.20	161,033
11/16/2020	Sell	30,000	$31.77	$953,100.00	166,293
11/13/2020	Sell	10,000	$31.87	$318,700.00	166,293
9/29/2020	Sell	1,781	$28.63	$50,990.03	56,293
3/5/2020	Sell	10,000	$13.72	$137,200.00	35,859
2/7/2020	Sell	10,000	$13.32	$133,200.00	35,859
2/5/2020	Sell	10,000	$14.06	$140,600.00	35,859
1/7/2020	Sell	10,000	$15.46	$154,600.00	35,859
12/5/2019	Sell	10,000	$16.19	$161,900.00	35,859
11/7/2019	Sell	10,000	$17.08	$170,800.00	35,859
10/4/2019	Sell	10,000	$15.63	$156,300.00	35,859
10/2/2019	Sell	10,000	$15.76	$157,600.00	35,859
9/6/2019	Sell	10,000	$19.88	$198,800.00	35,859
9/4/2019	Sell	10,000	$19.46	$194,600.00	35,859
8/2/2019	Sell	30,000	$18.96	$568,800.00	35,859
7/31/2019	Sell	10,000	$19.17	$191,700.00	35,859
7/3/2019	Sell	10,000	$16.09	$160,900.00	35,859
7/1/2019	Sell	10,000	$17.23	$172,300.00	35,859
6/19/2019	Sell	10,000	$17.60	$176,000.00	35,859
5/23/2019	Sell	14,500	$17.88	$259,260.00	25,859
5/16/2019	Sell	10,000	$16.76	$167,600.00	40,359
4/17/2019	Sell	10,000	$16.53	$165,300.00	40,359
3/20/2019	Sell	10,000	$19.83	$198,300.00	40,359
2/20/2019	Sell	10,000	$17.23	$172,300.00	24,583
1/17/2019	Sell	10,000	$12.49	$124,900.00	24,583
12/19/2018	Sell	10,000	$10.67	$106,700.00	24,583
10/17/2018	Sell	10,000	$12.95	$129,500.00	24,583
9/19/2018	Sell	10,000	$17.22	$172,200.00	24,583
8/16/2018	Sell	10,000	$19.10	$191,000.00	24,583
7/18/2018	Sell	10,000	$20.00	$200,000.00	24,583
5/29/2018	Sell	15,000	$9.65	$144,750.00	24,583
5/25/2018	Sell	10,000	$9.35	$93,500.00	24,583

Roderick de Greef Buying and Selling Activity at BioLife Solutions

BioLife Solutions Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $23.40

$23.12

$23.88

50 Day Range

MA: $24.09

$21.61

$25.98

2 Week Range

Now: $23.40

$8.98

$26.73

Volume

341,938 shs

Average Volume

368,256 shs

Market Capitalization

$1.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Roderick de Greef Biography and Net Worth

What is Roderick de Greef's net worth?

How old is Roderick de Greef?

What is Roderick de Greef's salary?

How do I contact Roderick de Greef?

Has Roderick de Greef been buying or selling shares of BioLife Solutions?

Who are BioLife Solutions' active insiders?

Are insiders buying or selling shares of BioLife Solutions?